- Profit after tax (consolidated)
- Rs 2,714.0 mn
- EPS
- Rs 51.22 +1.2%
- EPS a year earlier
- Rs 50.59
PSX Pharmaceuticals
HINOON Highnoon Laboratories Limited
Latest results: FY2025 · Dec 2025 Q2 FY2026 · Apr – Jun 2026
FY2025 revenue Rs 27.7 bn (+12.4%), profit Rs 4.1 bn (+21.8%). Dividend paid 20 years in a row.
Last close · 13 Nov 2026
Rs 959.62 ▲ 3.50 (+0.37%)
▼ 14.8% 1 year
- Market cap
- Rs 50.8 bn
- P/E
- 12.8×
- TTM to Jun 2026
- Sector 12.6×
- P/B
- 3.95×
- Quarter to Jun 2026
- Sector 3.11× · higher
- Dividend yield
- 5.2%
- FY2025
- Payers 4.7% · higher
- ROE
- 32.3%
- FY2025
- Sector 21.7% · higher
- EPS
- Rs 74.77
- TTM to Jun 2026
- Book value / share
- Rs 243.23
- Quarter to Jun 2026
Fundamentals
HINOON at a glance
Revenue · FY2025
Rs 27.7 bn
▲ 12.4% year on year
Profit attributable to shareholders · FY2025
Rs 4.1 bn
▲ 21.8% year on year
EPS – basic (Rs) · FY2025
Rs 77.92
▲ 21.8% year on year
Dividend per share (Rs) · FY2025
Rs 50.00
▲ 25.0% year on year
Net margin · FY2025
14.9%
+1.1 pts year on year
Debt to equity · FY2025
5.8%
-5.8 pts year on year
Price performance
HINOON returns
Close Rs 959.62
13 Nov 2026
| Period | Return | Rs | vs KSE-100 |
|---|---|---|---|
| MTD Month to date | +4.3% −2.6 pts vs KSE | +39.11 | −2.6 pts KSE +6.9% |
| 3M 3 months | −4.4% −3.1 pts vs KSE | −43.92 | −3.1 pts KSE −1.2% |
| 6M 6 months | +0.8% −5.4 pts vs KSE | +7.94 | −5.4 pts KSE +6.2% |
| YTD Year to date | −6.2% −8.3 pts vs KSE | −62.87 | −8.3 pts KSE +2.2% |
| 1Y 1 year | −14.8% −25.5 pts vs KSE | −166.88 | −25.5 pts KSE +10.7% |
| Long term | |||
| 3Y 3 years | +113.6% +28.8% a year −101.1 pts vs KSE | +510.34 | −101.1 pts KSE +214.7% |
| 5Y 5 years | +114.3% +16.5% a year −174.5 pts vs KSE | +511.90 | −174.5 pts KSE +288.8% |
Price return from the last close before each period; the fiscal year ends 31 December, so year to date is also fiscal year to date. Dividends are not included.
Highnoon Laboratories Limited in brief
Highnoon Laboratories Limited (HINOON) reported revenue of Rs 27.7 bn for FY2025 (Jan – Dec 2025), up 12.4% from FY2024.
Profit attributable to shareholders was Rs 4.1 bn (EPS Rs 77.92), up 21.8%, a net margin of 14.9%.
It declared a dividend of Rs 50.00 per share for FY2025 and has paid a dividend in each of the last 20 years.
The balance sheet showed net cash of Rs 2.8 bn.
Return on equity was 32.3%.
Over the last five years revenue grew at a compound 21.0% a year.
At Rs 959.62 (close on 13 Nov 2026) the shares trade at 12.8× earnings (TTM to Jun 2026) and 3.95× book value, with a dividend yield of 5.2%.
Scorecard vs Pharmaceuticals
14 companies- Growth
- Above average
- 20.5%
- Profitability
- Strong
- 14.9%
- Financial health
- Average
- 5.8%
- Valuation
- Average
- 12.8×
- Dividends
- Strong
- 5.2%
Ratings place the company in its sector: growth (3-year revenue growth), profitability (net margin; return on equity for banks, insurers and finance companies), financial health (debt to equity, industrial companies), valuation (P/E at today's price) and dividends (yield at today's price). Five dots = top fifth. Rated within the sector when at least four companies report the figure, otherwise against all PSX companies of the same type (marked vs PSX). Information, not investment advice.
Corporate
HINOON announcements & payouts
- Profit after tax (unconsolidated)
- Rs 2,621.1 mn
- EPS
- Rs 49.47 -2.2%
- EPS a year earlier
- Rs 50.59
- Profit after tax (consolidated)
- Rs 1,783.2 mn
- EPS
- Rs 33.66 +2.8%
- EPS a year earlier
- Rs 32.75
- Profit after tax (unconsolidated)
- Rs 1,677.5 mn
- EPS
- Rs 31.66 -3.3%
- EPS a year earlier
- Rs 32.75
Financial highlights
HINOON financial results
| Rs bn | FY2025 * Jan – Dec 2025 | FY2024 * Jan – Dec 2024 | FY2023 Jan – Dec 2023 | FY2022 * Jan – Dec 2022 | FY2021 Jan – Dec 2021 | FY2020 * Jan – Dec 2020 | FY2019 Jan – Dec 2019 | FY2018 Jan – Dec 2018 | FY2017 Jan – Dec 2017 | FY2016 * Jan – Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.7 | 24.6 | 19.8 | 15.8 | 13.0 | 10.7 | 9.0 | 7.5 | 6.0 | 5.1 |
| Gross profit | 15.2 | 12.5 | 9.4 | 8.2 | 6.5 | 5.2 | 4.2 | 3.5 | 2.9 | 2.4 |
| Operating profit | 6.3 | 5.0 | 3.4 | 3.2 | 2.3 | 1.9 | 1.3 | 1.1 | 0.9 | 0.8 |
| Profit after tax | 4.1 | 3.4 | 2.4 | 2.5 | 1.9 | 1.5 | 1.0 | 0.7 | 0.6 | 0.5 |
| Profit attributable to shareholders | 4.1 | 3.4 | 2.4 | 2.5 | 1.9 | 1.5 | 1.0 | 0.7 | 0.6 | 0.5 |
| EPS – basic (Rs) Rs | 77.92 | 63.95 | 46.20 | 46.67 | 35.04 | 27.82 | 18.89 | 13.82 | 12.89 | 11.11 |
| Dividend per share (Rs) Rs | 50.00 | 40.00 | 30.00 | 15.81 | 14.37 | 9.80 | 7.72 | 7.02 | 5.40 | 4.10 |
| Total assets | 19.4 | 17.2 | 14.7 | 11.0 | 8.4 | 6.6 | 4.7 | 3.9 | 3.5 | 2.9 |
| Total equity | 13.8 | 11.8 | 10.0 | 7.7 | 5.9 | 4.6 | 3.4 | 2.8 | 2.4 | 1.8 |
| Total debt | 0.8 | 1.4 | 1.4 | 0.8 | 0.4 | 0.5 | 0.2 | 0.2 | 0.2 | 0.1 |
| Net cash from operating activities | 1.8 | 4.5 | 1.8 | (0.2) | 1.8 | 1.5 | 0.7 | 0.5 | 0.3 | 0.6 |
| Capital expenditure | (0.5) | (0.3) | (0.8) | (0.9) | (0.3) | (0.4) | (0.3) | (0.1) | (0.2) | (0.2) |
| Free cash flow (operating cash flow − capex) | 1.4 | 4.2 | 1.0 | (1.0) | 1.5 | 1.1 | 0.5 | 0.4 | 0.1 | 0.4 |
| Rs bn | TTM to Jun 2026 | Q2 FY2026 Apr – Jun 2026 | Q1 FY2026 Jan – Mar 2026 | Q4 FY2025 Oct – Dec 2025 | Q3 FY2025 Jul – Sep 2025 | Q2 FY2025 Apr – Jun 2025 | Q1 FY2025 Jan – Mar 2025 | Q4 FY2024 Oct – Dec 2024 | Q3 FY2024 Jul – Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.3 | 6.5 | 7.5 | 7.4 | 6.9 | 6.2 | 7.0 | 6.3 | 6.3 |
| Gross profit | 15.8 | 3.7 | 4.4 | 4.0 | 3.8 | 3.6 | 3.7 | 3.3 | 3.2 |
| Operating profit | 6.4 | 1.0 | 1.9 | 2.3 | 1.2 | 1.3 | 1.3 | 1.8 | 1.0 |
| Profit after tax | 4.0 | 0.7 | 1.0 | 1.4 | 0.7 | 0.8 | 1.0 | 1.0 | 0.8 |
| Profit attributable to shareholders | 4.0 | 0.7 | 1.0 | 1.4 | 0.7 | 0.8 | 1.0 | 1.0 | 0.8 |
| EPS – basic (Rs) Rs | 74.77 | 13.87 | 19.78 | 27.32 | 13.79 | 14.74 | 18.02 | 18.73 | 14.09 |
| Dividend per share (Rs) Rs | 50.00 | 0.00 | 0.00 | 50.00 | 0.00 | 0.00 | 0.00 | 40.00 | 0.00 |
| Total assets | 18.4 | 18.4 | 21.2 | 19.4 | 18.1 | 16.3 | 18.0 | 17.2 | 17.1 |
| Total equity | 12.9 | 12.9 | 14.8 | 13.8 | 12.4 | 11.4 | 12.7 | 11.8 | 10.8 |
| Total debt | 1.1 | 1.1 | 1.2 | 0.8 | 0.3 | 0.6 | 0.6 | 1.4 | 1.2 |
| Net cash from operating activities | 3.4 | 1.9 | 0.5 | 1.2 | (0.2) | 0.9 | 0.0 | 0.9 | 1.4 |
| Capital expenditure | (0.8) | (0.4) | (0.2) | (0.1) | (0.2) | (0.4) | (0.1) | (0.0) | (0.4) |
| Free cash flow (operating cash flow − capex) | 2.6 | 1.5 | 0.3 | 1.2 | (0.4) | 0.5 | (0.1) | 0.9 | 1.0 |
Figures in Pakistani rupees as reported by the company; costs and cash outflows in brackets. Free cash flow and book value per share are calculated by Smart Money; TTM = the latest four quarters. * Some FY2025 figures do not fully reconcile in the source data. Updated 17 Oct 2026.
HINOON charts
Valuation
HINOON valuation at today's price
- Price to earnings (P/E)
- 12.8×
- EPS Rs 74.77 (TTM to Jun 2026)
- Price to book (P/B)
- 3.95×
- Book value Rs 243.23 (Quarter to Jun 2026)
- Dividend yield
- 5.2%
- DPS Rs 50.00 (FY2025)
- Earnings yield
- 7.8%
- EPS ÷ price
At the closing price of Rs 959.62 on 13 Nov 2026. P/E and P/B are not shown when earnings or book value are negative.
Sector peers
HINOON vs Pharmaceuticals companies
| Company | Market cap | P/E | P/B | Yield | ROE | 3-yr growth |
|---|---|---|---|---|---|---|
| HINOON | Rs 50.8 bn | 12.8× | 3.95× | 5.2% | 32.3% | 20.5% |
| GLAXO | Rs 107.1 bn | 10.3× | 3.11× | 5.1% | 32.4% | 16.3% |
| ABOT | Rs 97.9 bn | 11.4× | 3.05× | 4.0% | 28.8% | 15.2% |
| HALEON | Rs 81.6 bn | 12.4× | 5.02× | 4.3% | 47.6% | 16.2% |
| AGP | Rs 43.8 bn | 11.7× | 2.92× | 5.1% | 25.9% | 26.0% |
| HPL | Rs 38.5 bn | 10.3× | 4.50× | 6.0% | 38.6% | 18.6% |
| FEROZ | Rs 15.8 bn | 16.1× | 1.19× | 1.5% | 7.6% | 27.9% |
| CPHL | Rs 14.5 bn | 18.3× | 1.34× | 0.0% | 7.3% | 4.3% |
| MACTER | Rs 12.0 bn | 17.7× | 2.87× | 0.0% | 17.4% | 20.7% |
Analyses & signals 0
Win rate — · 0 closed signals · average return —
No analyses published for HINOON yet.
HINOON: frequently asked questions
What is HINOON's EPS?
Highnoon Laboratories Limited reported basic earnings per share of Rs 77.92 for FY2025 (Jan – Dec 2025). Over the trailing twelve months (TTM to Jun 2026) EPS was Rs 74.77.
What is HINOON's P/E ratio?
At the closing price of Rs 959.62 on 13 Nov 2026, HINOON trades at a P/E of 12.8× based on EPS of Rs 74.77 (TTM to Jun 2026).
Does HINOON pay dividends?
Yes. Highnoon Laboratories Limited declared a dividend of Rs 50.00 per share for FY2025. It has paid a dividend in each of the last 20 years. At Rs 959.62 that is a dividend yield of 5.2%.
What was HINOON's revenue and profit in FY2025?
Highnoon Laboratories Limited reported revenue of Rs 27.7 bn and profit attributable to shareholders of Rs 4.1 bn for FY2025 (Jan – Dec 2025).
What is HINOON's book value per share?
Highnoon Laboratories Limited's book value per share was Rs 259.57 at the end of FY2025. The shares trade at 3.95× book value.
How has HINOON's share price performed?
HINOON's share price is down 6.2% year to date (KSE-100: +2.2%), down 14.8% over one year (KSE-100: +10.7%) and up 114.3% over five years (KSE-100: +288.8%), as of 13 Nov 2026. These are price returns; dividends are not included.
Information only, not investment advice.